AGN241751

Zelquistinel is an oral drug in Phase 2 for major depressive disorder that tries to hit the same brain switch as ketamine but without the trip. Syndeio Biosciences, a private neuroscience company launched in May 2025 with over $90M in funding, is running two placebo-controlled Phase 2 trials of 164 patients each, measuring depression symptoms on the standard HDRS-17 scale [1][2][12]. The compound has been passed between owners: it began at Naurex, moved to Allergan as AGN-241751, then to Aptinyx, and after Aptinyx's collapse (Phase 2 failures in 2022, dissolution plan announced May 2023, legally completed January 2024) landed at Syndeio via Gate Neurosciences [7]. If it works, an oral NMDA modulator patients could take at home would sidestep the biggest limitation of ketamine and Spravato (esketamine), which require in-clinic dosing and monitoring for dissociation. That's the pitch. The catch: rapastinel, from the same Naurex discovery lineage, produced positive Phase 2 signals and then failed three consecutive Phase 3 trials in MDD in March 2019 (NCT02932943, NCT02943564, NCT02943577) [6]. This is a class carrying real ghosts.

Zelquistinel is a first-in-class investigational compound with no approvals anywhere. Two Phase 2 trials are actively recruiting: NCT06547489 and NCT07115329, both sponsored by Syndeio Biosciences, both n=164, both using HDRS-17 change versus placebo as the primary endpoint [1][2]. A prior Phase 2 (NCT03586427) run under the Aptinyx era enrolled 251 patients and completed with MADRS as the endpoint [3]. A Phase 1 study (NCT03726658) enrolled 226 patients [4]. A food-effect PK study (NCT07099989) is active and not recruiting [5]. No public FDA breakthrough, fast track, or orphan designation has been announced for this program. Detailed topline results from NCT03586427 have not been publicly disclosed, which is itself informative: a clean win in MDD typically prompts a press release within months of database lock. Syndeio is a private company, so financial disclosures and go-forward runway are not visible in SEC filings. Expected readout for the current Phase 2 program has not been guided. With both trials still recruiting toward 164-patient targets as of mid-2026, topline is unlikely before late 2027 at the earliest, assuming steady site activation and enrollment.

The NMDA receptor is a channel on brain cells that opens when glutamate (the main excitatory chemical messenger in the brain) binds to it. When open, it lets calcium into the neuron, and that calcium influx triggers the molecular changes that let neurons strengthen their connections. Neuroscientists call this synaptic plasticity, and it's how the brain learns. Something about that plasticity signal appears to be broken in depression. Ketamine, an anesthetic that plugs the NMDA channel, produces antidepressant effects within hours rather than the weeks SSRIs take. That finding is the strongest evidence any target has for a fundamentally different mechanism than serotonin drugs, and Janssen's Spravato (esketamine) reached approximately $1.7B in 2024 revenue on it [8]. The NMDA receptor is a tetramer, typically built from two GluN1 subunits paired with two GluN2 subunits (GluN2A, GluN2B, GluN2C, or GluN2D). Different subunit combinations have different regional distributions in the brain and different roles in plasticity. Rapastinel, the failed predecessor from the Naurex lineage, was historically characterized as a partial agonist at the glycine coagonist site on the GluN1 subunit, though more recent structural work suggests it engages a novel site rather than the glycine pocket directly [6]. Zelquistinel is mechanistically distinct on three axes. First, it binds an extracellular site on the NMDA receptor complex that is independent of both the glutamate and glycine ligand sites, and it acts by reducing calcium-dependent inactivation so the receptor stays active longer once glutamate binds [11]. Second, it engages GluN2A, GluN2B, and GluN2C-containing receptors while sparing GluN2D, with the largest ceiling enhancement observed at GluN2B; this GluN2B-weighted profile is where the subunit-selectivity differentiation claim comes from [11]. Third, it is orally bioavailable where rapastinel was IV. The hypothesis for why this profile might succeed where rapastinel failed: enhancing plasticity through calcium-dependent inactivation at a GluN2B-weighted profile could produce a cleaner efficacy signal than glycine-site engagement, with less off-target NMDA activity. The honest counter: there is no clinical evidence that subunit selectivity, binding site, or calcium-inactivation mechanism was what rapastinel lacked. If rapastinel's Phase 3 failures reflected placebo-response inflation in modern MDD trials rather than a target-engagement problem, mechanistic refinement will not rescue zelquistinel.

The two active Phase 2 trials, NCT06547489 and NCT07115329, are each randomized and placebo-controlled, each targeting 164 patients with MDD, and each using change in HDRS-17 (the 17-item Hamilton Depression Rating Scale) as the primary endpoint [1][2]. NCT07115329 is titled to include comorbid anxiety and insomnia, which suggests Syndeio is scoping toward a real-world depressed population rather than a scrubbed monotherapy cohort. Running two parallel Phase 2 studies of identical size implies either an internal replication strategy to strengthen a borderline signal, or a way to distribute enrollment risk across sites and geographies. Both interpretations fit an MDD program because placebo response is the central design problem in this indication: placebo arms routinely improve 6 to 10 HDRS points, and any drug effect has to clear that noise floor. The 164-patient size (roughly 82 per arm) is modest by modern MDD standards, where well-powered Phase 2s often run 200 to 400 patients per arm. This is a bet on a moderate-to-large effect size.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk dominates, and two prior-program signals compound it. First, rapastinel produced positive Phase 2 signals in the same target class and then failed three consecutive Phase 3 MDD trials in 2019 (NCT02932943, NCT02943564, NCT02943577), erasing hundreds of millions in Allergan investment [6]. Second, the prior zelquistinel Phase 2 (NCT03586427, n=251) completed under Aptinyx with MADRS as the primary endpoint, and results were never publicly disclosed. Syndeio switched the primary endpoint to HDRS-17 for the current Phase 2 program. In MDD development, an undisclosed completed Phase 2 combined with a primary-scale switch is a strong negative prior: switching endpoints between programs is almost universally a sign that the earlier scale did not produce what the sponsor needed. Whether zelquistinel escapes rapastinel's fate depends on whether earlier Phase 2 hits in this class were real underpowered effects or placebo-response artifacts, and the current program enters Phase 3 (if it gets there) without even the benefit of a clean Phase 2 precedent to lean on. Safety risk is comparatively lower for a positive allosteric modulator than for a channel blocker like ketamine. A PAM should not reproduce ketamine's deep dissociation and abuse liability at therapeutic doses, though NMDA modulation of any kind carries a theoretical cognitive-effects burden, and the earlier NCT03726658 Phase 1 safety data has not been broadly published [4]. Execution risk is elevated but tempered by team pedigree. Syndeio is private with no visible SEC-disclosed runway, but the founding team includes Derek Small (previously founding CEO of Naurex, which discovered rapastinel and the broader NMDA-modulator series, later acquired by Allergan), John Donello (former VP External Innovation at Allergan), Michael McCully (from Gate Neurosciences), and Thomas Südhof (Nobel laureate, Stanford). Backers include Catalio Capital, Innoviva, Tenmile, Luson Bioventures, and Palo Santo, with AbbVie and Lilly as strategic shareholders on over $90M raised [12]. Team and syndicate are unusually credentialed for a private CNS asset; execution risk is real but not naive. Commercial risk sits on three fronts. Spravato is entrenched in treatment-resistant depression at approximately $1.7B in 2024 revenue and growing [8]. Axsome's Auvelity (dextromethorphan-bupropion), approved 2022, generated $291M in 2024 net product revenue in MDD [9]. And the most direct competitor for an oral at-home NMDA-modulator pitch is the ketamine infusion clinic ecosystem, which operates outside REMS constraints, treats depression off-label at scale, and undercuts the clinic-visit burden that Spravato carries. Zelquistinel would need faster onset than Auvelity, better tolerability than Spravato, or a real convenience edge on ketamine clinics to displace any of them in a prescribing decision.

Worth watching, not urgently. The specific signal that would matter: Phase 2 topline from NCT06547489 or NCT07115329 showing HDRS-17 separation of roughly 3 points or more versus placebo at week 4 or 6. That threshold matters because approved MDD drugs (SSRIs, SNRIs, Auvelity, Spravato) typically show drug-versus-placebo separations of 2 to 4 HDRS or MADRS points at primary endpoints; anything below 2 tends not to survive FDA review, and anything above 4 is unusual. The fact that detailed results from the earlier Aptinyx-era Phase 2 (NCT03586427) were never broadly published, combined with the MADRS-to-HDRS-17 endpoint switch, is not a good sign for what the current studies will produce [3]. Syndeio is a private neuroscience shop, so the cheapest ongoing signal is any partnership or milestone disclosure that surfaces through investor filings, and given AbbVie and Lilly are already on the cap table, watch for any expanded strategic activity from either [12]. Check back Q4 2027 when at least one of the current Phase 2 trials should have topline data if enrollment holds pace. Before then, watch for FDA breakthrough or fast track designations (either would be a real positive), ASCP or SOBP conference disclosures, and any partnership announcement. For public-market investors, there is no direct way to play this asset. For biotech scouts and licensing teams, the mechanistic thesis is legitimate and the team pedigree is real, but three prior owners could not produce a Phase 3 winner from this discovery lineage. Whether Syndeio can execute where Naurex, Allergan, and Aptinyx could not, on a differentiated but clinically-unproven mechanistic axis, is the open question.